Gastrointestinal Stromal Neoplasm clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
open to eligible people ages 18 years and up
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Gastrointestinal Stromal Neoplasm research studies include Arun S. Singh, MD.
Last updated: